NASDAQ:CNSP CNS Pharmaceuticals Q2 2025 Earnings Report $5.22 -0.30 (-5.43%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CNS Pharmaceuticals EPS ResultsActual EPS-$6.42Consensus EPS -$9.60Beat/MissBeat by +$3.18One Year Ago EPSN/ACNS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACNS Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETUpcoming EarningsCNS Pharmaceuticals' Q2 2026 earnings is estimated for Monday, May 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CNS Pharmaceuticals Earnings HeadlinesWhat's going on with CNS Pharmaceuticals stock on Wednesday?May 6, 2026 | msn.comCNS Pharmaceuticals Announces Private Placement and Board ChangesMay 6, 2026 | theglobeandmail.comDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - says hundreds of trillions of dollars are about to move through a new financial technology that has nothing to do with AI. Goldman Sachs, Citi, Chase, and 50-plus major institutions are already preparing. A key piece of legislation expected before July could fast-track global adoption. Jeff is sharing his full research at no charge.May 14 at 1:00 AM | Brownstone Research (Ad)Why did CNSP stock surge 330% today?May 5, 2026 | msn.comCNS Pharmaceuticals (CNSP) soars 311.7% as investors react to $22.5M oversubscribed private placementMay 4, 2026 | quiverquant.comQCNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingMay 4, 2026 | finance.yahoo.comSee More CNS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email. Email Address About CNS PharmaceuticalsCNS Pharmaceuticals (NASDAQ:CNSP), headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment. Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development. WP1066 is in preclinical stages with plans to progress to early-phase clinical studies, targeting patients who have limited treatment options due to the highly immunosuppressive nature of central nervous system tumors. Together, these candidates reflect the company’s strategy to address both direct cytotoxic and immune-mediated approaches to brain cancer therapy. Under the leadership of Chairman and Chief Executive Officer Howard J. Robin, CNS Pharmaceuticals completed its initial public offering on the NASDAQ Capital Market under the symbol CNSP. The company conducts clinical trials across North America and collaborates with academic and research institutions to support its development programs. With a dedicated focus on unmet needs in neuro-oncology, CNS Pharmaceuticals aims to advance its pipeline toward regulatory approvals and ultimately provide new treatment options for patients with life-threatening brain tumors.View CNS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisChime Finally Turns Profitable—But Risks RemainHow Berkshire’s New York Times Bet Looks TodayPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
